Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23220348 | 1.00 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2GPR55HSD17B10NPSR1 | |
| SCHEMBL24758640 | 0.89 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2GPR55HSD17B10NPSR1 | |
| SCHEMBL2605819 | 0.82 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2GPR55HSD17B10NPSR1 | |
| SCHEMBL26218004 | 0.82 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2HSD17B10KMT2AMEN1 | |
| SCHEMBL22570461 | 0.81 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2NPSR1EPHX2P2RX7 | |
| SCHEMBL11571843 | 0.80 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2GPR55NPSR1EPHX2 | |
| SCHEMBL16158150 | 0.80 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2NPSR1EPHX2P2RX7 | |
| SCHEMBL26334226 | 0.79 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2NPSR1EPHX2P2RX7 | |
| SCHEMBL5098102 | 0.79 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2NPSR1EPHX2P2RX7 | |
| SCHEMBL3454752 | 0.79 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2GPR55NPSR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4249480-A1 | DIPHENYLPYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Northwest A&F University (CN) | 2023-09-27 | — | — | EP | disclosed |
| WO-2020141734-A1 | METHOD FOR PREPARING CHIRAL GAMMA-LACTAM COMPOUND AND METAL COMPLEX THEREFOR | 기초과학연구원 | 2020-07-09 | — | — | WO | disclosed |
| WO-2018125992-A1 | FUNCTIONALIZED NANOLUC INHIBITORS | PROMEGA CORPORATION (US) | 2018-07-05 | — | — | WO | disclosed |
| US-20130172549-A1 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-8431593-B2 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-04-30 | — | — | US | disclosed |
| US-7923461-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-04-12 | — | — | US | disclosed |
| EP-1568692-B1 | (Pyridinyl)alkyl-amides or -ureas as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | H. LUNDBECK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| US-7741346-B2 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20100016380-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1743885-A2 | TNF-Alpha Produktion Hemmer zur Behandlung von Autoimmunerkrankungen | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| US-20060229342-A1 | TNF-a production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| US-7098226-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| EP-1568692-A1 | (pyridin-4-yl)alkyl-amides as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1561749-A1 | TNF-Alpha production inhibitors for the treatment of autoimmune diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-10 | — | — | EP | disclosed |
| US-20050014800-A1 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1457205-A1 | ANGIOGENESIS INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-09-15 | — | — | EP | disclosed |
| EP-1302461-A1 | TNF-ALPHA PRODUCTION INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20030032623-A1 | Tnf-alpha production inhibitors | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | TNFRSF1A, FFAR4, NGFR | ALDH1A1 557/4885SMN1; SMN2 4392/4885GPR55 261/4885 |
| US-20060229342-A1 | TNF-a production inhibitors | TNF, TNFRSF1A, TNFRSF9 | ALDH1A1 950/4885SMN1; SMN2 4499/4885GPR55 365/4885 |
| US-20050014800-A1 | Angiogenesis inhibitor | FLT4, KDR, FLT1 | ALDH1A1 1011/4885SMN1; SMN2 4717/4885GPR55 364/4885 |
| US-20030032623-A1 | Tnf-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | ALDH1A1 556/4885SMN1; SMN2 4171/4885GPR55 783/4885 |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | HCAR2, PIGS, GPR52 | ALDH1A1 1276/4885SMN1; SMN2 3884/4885GPR55 45/4885 |
| US-20100016380-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | ALDH1A1 1792/4885SMN1; SMN2 4681/4885GPR55 1198/4885 |
| US-20130172549-A1 | Heteroaryl amide derivatives | HCAR2, PIGS, GPR52 | ALDH1A1 1276/4885SMN1; SMN2 3884/4885GPR55 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.